ClinicalTrials.gg

Program

tivunatamig

Also written as “PF-08634404” and “SSGJ-707”.

In Pfizer’s pipeline, PD-1xVEGF Bispecific Antibody. Its studies are mostly in Endometrial Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Oct 28, 202515 company-led studies, 15 open or runningLicense: 3SBio → Pfizer, May 2025Next primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer1010 open or runningphase 3since Oct 28, 2025Oct 28, 2025Oct 18, 2027phase 2 · NCT07227012
3SBio55 open or runningphase 3since May 12, 2025Apr 8, 2024none ahead
  • Named in Pfizer’s own pipeline as tivunatamig PF-08634404, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Astellas Pharma.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2024First studies: 2 phase 2 studiesNew to 3SBio3SBio · NCT06361927, NCT06412471
  2. Jun 25, 2024Phase 2 study in Colorectal Neoplasms3SBio · NCT06493760 · 130 planned · China
  3. Jul 22, 2024Phase 2 study in Endometrial Neoplasms3SBio · NCT06522828 · 80 planned · China
  4. May 12, 2025Phase 3 study in Advanced Non-Small Cell Lung Cancer3SBio · NCT06980272 · 420 planned · China
  5. May 19, 2025Pfizer licensed it from 3SBioLicenseEverywhere outside China, with an option on China · announced · Pfizer (release)
  6. Oct 28, 2025Pfizer’s first studies: 2 phase 3 studiesNew to PfizerPfizer · NCT07222800, NCT07222566
  7. Nov 7, 20252 phase 2 studiesPfizer · NCT07227415, NCT07227012
  8. Nov 7, 2025Phase 3 study in Small Cell Lung CarcinomaPfizer · NCT07226999 · 550 planned · United States, Australia, China and more
  9. Jan 30, 2026Phase 3 study in Stomach NeoplasmsPfizer · NCT07392892 · 840 planned · United States, Canada, China and more
  10. Feb 12, 2026Phase 2 study in Carcinoma, Transitional CellPfizer · NCT07421700 · 132 planned · United States, Australia, China and more
  11. Mar 13, 20262 phase 2 studiesPfizer · NCT07476287, NCT07489066
  12. May 5, 2026Phase 3 study in Endometrial NeoplasmsPfizer · NCT07578649 · 600 planned · United States, Australia, China and more
  13. Sep 28, 2026Primary completion moved from 2031-07-22 to 2032-01-15Date moved laterphase 3 · +6 months · NCT07392892

Ahead

  1. Oct 18, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularPfizer · NCT07227012
  2. Nov 2, 2027Primary completion: phase 2 study in Carcinoma, Renal CellPfizer · NCT07227415
  3. Dec 28, 2027Primary completion: phase 2 study in Carcinoma, Transitional CellPfizer · NCT07421700
  4. Mar 24, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaPfizer · NCT07476287

TargetBeta

“PD-1xVEGF Bispecific Antibody”the company's pipeline, read by Claude · source
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and an…”NCIt, read by Claude
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07578649Endometrial Neoplasms · United States, Australia, China and more3RecruitingPfizerJun 1, 2029600
NCT07489066Carcinoma · United States, Australia, China and more2RecruitingPfizerJul 29, 2028120
NCT07476287Small Cell Lung Carcinoma · United States, Australia, Brazil and more2RecruitingPfizerMar 24, 202840
NCT07421700Carcinoma, Transitional Cell · United States, Australia, China and more2RecruitingPfizerDec 28, 2027132
NCT07392892Stomach Neoplasms · United States, Canada, China and more3RecruitingPfizerJul 22, 2031840
NCT07227415Carcinoma, Renal Cell · United States, Australia, China and more2RecruitingPfizerNov 2, 2027224
NCT07227012Carcinoma, Hepatocellular · United States, China, Japan and more2RecruitingPfizerOct 18, 2027138
NCT07226999Small Cell Lung Carcinoma · United States, Australia, China and more3RecruitingPfizerJun 14, 2030550
NCT07222800Intestinal Neoplasms · United States, Argentina, Australia and more3RecruitingPfizerFeb 23, 2030800
NCT07222566Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingPfizerFeb 27, 20291,410
NCT06980272Advanced Non-Small Cell Lung Cancer · China3Recruiting3SBioJul 30, 2026420
NCT06522828Endometrial Neoplasms · China2Recruiting3SBioAug 202580
NCT06493760Colorectal Neoplasms · China2Recruiting3SBioJun 2025130
NCT06412471First-line Advanced NSCLC Patients · China2Recruiting3SBioJul 2025235
NCT06361927NSCLC · China2Recruiting3SBioJun 2025120

How it is read

Names in the registry

  • “PF-08634404”, 10 entries
  • “SSGJ-707”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.